Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin and Pucotenlimab in Advanced Penile Cancer
NCT07497919Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2026
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in penile squamous cell carcinoma (PSCC), sponsored by Fudan University. Started Sep 2026; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT07497919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497919.